This CPB has been revised to add medical necessity criteria for plaque psoriasis (PsO) and psoriatic arthritis (PsA) which was previously in CPB 0658 - Psoriasis and Psoriatic Arthritis: Targeted Immune Modulators. This CPB has been revised with the following: (i) added prescriber specialty requirements for all indications, (ii) added 'adult' member requirement to the criteria for all indications, (iii) for PsA, (a) initial criteria, added requirement for members who previously received a biologic or targeted synthetic drug for PsA, mild to moderate disease with inadequate response to MTX or other conventional synthetic drug, or severe disease, and (b) for continuation therapy, removed 'active' disease requirement and added improvement in axial disease as an option; (iv) for PsO, added initial approval if previously received a targeted synthetic drug; and (v) added examples of clinical reasons to avoid pharmacologic treatment with methotrexate, cyclosporine or acitretin to the appendix.